IL234831B - Medical preparations for combined treatment - Google Patents

Medical preparations for combined treatment

Info

Publication number
IL234831B
IL234831B IL234831A IL23483114A IL234831B IL 234831 B IL234831 B IL 234831B IL 234831 A IL234831 A IL 234831A IL 23483114 A IL23483114 A IL 23483114A IL 234831 B IL234831 B IL 234831B
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
combination therapy
therapy
combination
pharmaceutical
Prior art date
Application number
IL234831A
Other languages
English (en)
Hebrew (he)
Other versions
IL234831A0 (en
Inventor
Ross Nicholas Waters
Eva Susanna Waters
Original Assignee
Ross Nicholas Waters
Eva Susanna Waters
Prilenia Neurotherapeutics Ltd
Teva Pharmaceuticals Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ross Nicholas Waters, Eva Susanna Waters, Prilenia Neurotherapeutics Ltd, Teva Pharmaceuticals Int Gmbh filed Critical Ross Nicholas Waters
Publication of IL234831A0 publication Critical patent/IL234831A0/en
Publication of IL234831B publication Critical patent/IL234831B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/01Hydrolysed proteins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL234831A 2012-04-04 2014-09-23 Medical preparations for combined treatment IL234831B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261620203P 2012-04-04 2012-04-04
US201261625192P 2012-04-17 2012-04-17
US201361783730P 2013-03-14 2013-03-14
PCT/US2013/035124 WO2013152105A1 (en) 2012-04-04 2013-04-03 Pharmaceutical compositions for combination therapy

Publications (2)

Publication Number Publication Date
IL234831A0 IL234831A0 (en) 2014-12-31
IL234831B true IL234831B (en) 2020-10-29

Family

ID=49292803

Family Applications (1)

Application Number Title Priority Date Filing Date
IL234831A IL234831B (en) 2012-04-04 2014-09-23 Medical preparations for combined treatment

Country Status (16)

Country Link
US (3) US20130267552A1 (enExample)
EP (1) EP2844346B1 (enExample)
JP (1) JP6177875B2 (enExample)
KR (1) KR20150013476A (enExample)
CN (1) CN104470585A (enExample)
AU (1) AU2013243461A1 (enExample)
BR (1) BR112014024672A8 (enExample)
CA (1) CA2869145A1 (enExample)
EA (1) EA027748B1 (enExample)
ES (1) ES2776678T3 (enExample)
HK (1) HK1206297A1 (enExample)
IL (1) IL234831B (enExample)
MX (1) MX2014011971A (enExample)
NZ (1) NZ630560A (enExample)
WO (1) WO2013152105A1 (enExample)
ZA (1) ZA201407726B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
PT2146961E (pt) * 2007-04-12 2014-04-30 Ivax Int Gmbh Derivados de n-óxido e/ou di-n-óxido de estabilizadores / moduladores dos recetores da dopamina exibindo perfis de efeitos secundários cardiovasculares melhorados
SG10201506761XA (en) 2010-09-03 2015-10-29 Teva Pharmaceuticals Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
CA2847736A1 (en) 2011-09-07 2013-03-14 IVAX International GmbH A new polymorphic form of pridopidine hydrochloride
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
MX384234B (es) 2013-06-21 2025-03-14 Prilenia Neurotherapeutics Ltd Uso de pridopidina para el tratamiento de enfermedad de huntington.
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
US20150202302A1 (en) * 2014-01-22 2015-07-23 IVAX International GmbH Modified release formulations of pridopidine
CA2946518C (en) * 2014-04-25 2022-07-26 Chugai Seiyaku Kabushiki Kaisha Preparation containing tetracyclic compound at high dose
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
MX2017008136A (es) 2014-12-22 2018-03-06 Teva Pharmaceuticals Int Gmbh Sal de l-tartrato de pridopidina.
EP4282479A3 (en) 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
US11738012B2 (en) 2016-02-24 2023-08-29 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
BR112019003732A2 (pt) 2016-08-24 2020-02-18 Prilenia Therapeutics Development Ltd. Aplicação de pridopidina para tratamento de declínio funcional
DK3503890T3 (da) 2016-08-24 2025-01-27 Prilenia Neurotherapeutics Ltd Anvendelse af pridopidin til behandling af dystonier
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
MX388845B (es) 2016-09-16 2025-03-20 Prilenia Neurotherapeutics Ltd Uso de pridopidina para tratar el sindrome de rett.
JP7114604B2 (ja) 2017-01-20 2022-08-08 プリレニア ニューロセラピューティクス リミテッド 脆弱x症候群の治療のためのプリドピジンの使用
WO2019010491A1 (en) * 2017-07-07 2019-01-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS
EP3664787B1 (en) 2017-07-20 2022-07-20 Neurolixis Use of selective serotonin 5-ht1a receptor agonists for treating side-effects of vmat inhibitors
DK3668509T3 (da) 2017-08-14 2023-02-20 Prilenia Neurotherapeutics Ltd Fremgangsmåde til behandling af amyotrofisk lateralsklerose med pridopidin
MX2020002310A (es) 2017-08-30 2020-09-17 Prilenia Neurotherapeutics Ltd Formas de dosificacion de alta concentracion de pridopidina.
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
CN111343982A (zh) 2017-09-08 2020-06-26 普瑞尼亚神经治疗有限公司 用于治疗药物诱发的异动症的普利多匹定
WO2020110128A1 (en) * 2018-11-29 2020-06-04 Prilenia Neurotherapeutics Ltd. Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia
JP2021510971A (ja) * 2018-01-17 2021-04-30 ヒルシュマン カー コミュニケーション ゲゼルシャフト ミット ベシュレンクテル ハフツングHirschmann Car Communication GmbH 受信機システムから遠隔にあるlteモジュール
IL278185B2 (en) * 2018-04-25 2024-11-01 Shinkei Therapeutics Inc Tetrabenazine transdermal delivery device
JP7585561B2 (ja) 2019-02-04 2024-11-19 プリレニア ニューロセラピューティクス リミテッド パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン
IL297932A (en) * 2020-05-04 2023-01-01 Prilenia Neurotherapeutics Ltd Treatment of viral infection, disease or disorder using a selective s1r agonist

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB850662A (en) 1956-10-22 1960-10-05 Parke Davis & Co Substituted piperazines and processes for their production
BE662455A (enExample) 1964-04-14
GB1060160A (en) 1964-08-05 1967-03-01 Allen & Hanburys Ltd 4-phenylpiperidine derivatives
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
ZA7546B (en) 1974-01-21 1976-08-25 Parke Davis & Co New antibacterial amide compounds and methods for their production
US4048314A (en) 1974-12-17 1977-09-13 Delmar Chemicals Limited Morpholino containing 4-arylpiperidine derivatives
US4202898A (en) 1978-06-05 1980-05-13 Synthelabo Method of treating anxiety and depression
US4267328A (en) 1978-08-01 1981-05-12 Synthelabo 1-Phenylpiperazines
US4333942A (en) 1979-08-03 1982-06-08 Byk Gulden Lomberg Chemische Fabrik Gmbh Anti-depressant and analgesic 4-phenoxypiperidines
US4518712A (en) 1980-06-30 1985-05-21 Taiho Pharmaceutical Company Limited Piperazine derivative and analgesic composition containing the same
GB2083476B (en) 1980-09-12 1984-02-08 Wyeth John & Brother Ltd Heterocyclic compounds
FR2501506A1 (fr) 1981-03-11 1982-09-17 Sanofi Sa Compositions pharmaceutiques a action anorexigene contenant des derives de la tetrahydropyridine
US4415736A (en) 1981-12-28 1983-11-15 E. I. Du Pont De Nemours & Co. Certain tetrahydropyridine intermediates
US4485109A (en) 1982-05-07 1984-11-27 E. I. Du Pont De Nemours And Company 4-Aryl-4-piperidinecarbinols
ATE50987T1 (de) 1982-05-10 1990-03-15 Takeda Chemical Industries Ltd Dihydropyridinderivate, deren herstellung und verwendung.
US4504660A (en) 1982-07-06 1985-03-12 American Home Products Corporation Process for the production of 2,6-diaminobenzonitrile derivatives
DE3306964A1 (de) 1983-02-28 1984-09-06 Boehringer Ingelheim KG, 6507 Ingelheim Neues n-arylpiperazin und verfahren zu seiner herstellung
HU198454B (en) 1987-12-14 1989-10-30 Richter Gedeon Vegyeszet Process for production of new derivatives of tetrahydrospiridin and medical compositions containing these compounds
FR2639226B1 (fr) 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
JPH05503517A (ja) 1989-12-18 1993-06-10 バージニア・コモンウェルス・ユニバーシティ シグマレセプターリガンド及びその用途
DE69231854T2 (de) 1991-04-17 2001-10-04 Pharmacia & Upjohn Co., Kalamazoo Substituierte (s)-3-phenylpiperidin derivate, deren herstellung und deren verwendung als dopamin autorezeptor antagonisten
EP0591426A4 (en) 1991-06-27 1996-08-21 Univ Virginia Commonwealth Sigma receptor ligands and the use thereof
IE914218A1 (en) 1991-09-11 1993-03-24 Mcneilab Inc Novel 4-arylpiperazines and 4-arylpiperidines
DE69232003T2 (de) 1991-09-18 2002-04-25 Glaxo Group Ltd., Greenford Benzanilidderivate als 5-HT1D-Antagonisten
GB9119932D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
US5502050A (en) 1993-11-29 1996-03-26 Cornell Research Foundation, Inc. Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis
IL112099A (en) 1993-12-23 1999-07-14 Ortho Pharma Corp N-oxides of 4-arylpiperazines and 4-arylpiperidines and pharmaceutical compositions containing them
CA2144669A1 (en) 1994-03-29 1995-09-30 Kozo Akasaka Biphenyl derivatives
ZA954688B (en) 1994-06-08 1996-01-29 Lundbeck & Co As H Serotonin 5-HT1A and dopamin D2 receptor ligands
WO1997003986A1 (en) 1995-07-19 1997-02-06 Yoshitomi Pharmaceutical Industries, Ltd. Fused triazole compounds
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
EP0867183B1 (en) 1996-07-22 2004-10-06 Daiichi Suntory Pharma Co., Ltd. Arylpiperidinol and arylpiperidine derivatives and drugs containing the same
US5892041A (en) 1996-08-12 1999-04-06 Neurogen Corporation Fused indolecarboxamides: dopamine receptor subtype specific ligands
DE19637237A1 (de) 1996-09-13 1998-03-19 Merck Patent Gmbh Piperazin-Derivate
WO1998047885A1 (en) 1997-04-18 1998-10-29 Smithkline Beecham Plc A bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5ht1a, 5ht1b and 5ht1d receptor antagonistic activity
DE69704679T2 (de) 1997-06-10 2001-09-13 Synthon Bv 4-phenylpiperidin-derivate
SE9702716D0 (sv) 1997-07-15 1997-07-15 Ross Nicholas Waters Substituted phenylazacycloalkanes in the treatment of cognitive disorders
CA2267315C (en) * 1997-08-07 2008-01-08 Fujimoto Brothers Co., Ltd. Ethylamine derivatives
US6232326B1 (en) 1998-07-14 2001-05-15 Jodi A. Nelson Treatment for schizophrenia and other dopamine system dysfunctions
CA2351719A1 (en) 1998-11-23 2000-06-02 Sepracor Inc. Pharmaceutical compositions containing olanzapine-n-oxide
JP2003502405A (ja) 1999-06-22 2003-01-21 ニューロサーチ、アクティーゼルスカブ 新規ベンズイミダゾール誘導体及びこれらの化合物を含有する薬学的に容認された塩
WO2001008678A1 (en) 1999-07-30 2001-02-08 University Of Kentucky Research Foundation Cis-2,6-disubstituted piperidines for the treatment of psychostimulant abuse and withdrawal, eating disorders, and central nervous system diseases and pathologies
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
WO2002005819A1 (en) 2000-07-15 2002-01-24 Smithkline Beecham Corporation Compounds and methods
CA2431996A1 (en) 2001-01-23 2002-08-01 Vincent Mancuso Melanocortin receptor agonists
SE0200301D0 (sv) 2002-02-01 2002-02-01 Axon Biochemicals Bv Thio-carbostyril derivative
US20050004164A1 (en) 2003-04-30 2005-01-06 Caggiano Thomas J. 2-Cyanopropanoic acid amide and ester derivatives and methods of their use
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
EP2204363A1 (en) 2004-06-08 2010-07-07 NSAB, Filial af NeuroSearch Sweden AB, Sverige New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission
MXPA06013944A (es) 2004-06-08 2007-10-08 Neurosearch Sweden Ab Nuevas fenilpiperidinas/piperazinas disustituidas como moduladores de la neurotransmision de dopamina.
US7851629B2 (en) 2004-06-08 2010-12-14 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
CN101031300A (zh) 2004-10-01 2007-09-05 默克公司 用于治疗或预防糖尿病的作为二肽基肽酶-ⅳ抑制剂的氨基哌啶化合物
AU2005293754B2 (en) 2004-10-13 2011-07-21 Teva Pharmaceuticals International Gmbh Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine
AU2005293755A1 (en) 2004-10-13 2006-04-20 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Process for the synthesis of 4-(3-sulfonylphenyl)-piperidines
PT1919883E (pt) 2005-08-22 2009-03-26 Solvay Pharm Bv N-óxidos como pró-medicamentos de derivados de piperazina & piperidina
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
WO2007065655A1 (en) 2005-12-07 2007-06-14 Neurosearch Sweden Ab Disubstituted phenylpiperidines as modulators of cortical catecholaminergic neurotransmission
AU2007247251B2 (en) 2006-05-02 2011-11-03 Solvay Pharmaceuticals B.V. N-oxides of pyridylmethylpiperazine and -piperidine derivatives
US20090318500A1 (en) 2006-05-05 2009-12-24 Astex Therapeutics Limited 4-(2, 6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide for the Treatment of Cancer
EP1961742A1 (en) 2007-02-22 2008-08-27 Novartis AG compounds of formula (I) as serine protease inhibitors
US20100204258A1 (en) * 2007-03-12 2010-08-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for modulating insulin secretion and glucose metabolism
PT2146961E (pt) 2007-04-12 2014-04-30 Ivax Int Gmbh Derivados de n-óxido e/ou di-n-óxido de estabilizadores / moduladores dos recetores da dopamina exibindo perfis de efeitos secundários cardiovasculares melhorados
TW200848063A (en) * 2007-04-23 2008-12-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
CN101765428A (zh) * 2007-06-18 2010-06-30 A·卡尔森研究股份有限公司 多巴胺稳定剂的用途
WO2011019956A2 (en) * 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
JP2012508768A (ja) 2008-11-13 2012-04-12 リンク・メディスン・コーポレーション アザキノリノン誘導体及びその使用
MX2011013016A (es) * 2009-06-05 2012-04-20 Link Medicine Corp Derivados de aminopirrolidinona y usos de los mismos.
US20120122848A1 (en) 2009-07-29 2012-05-17 Green Cross Corporation (+)-3-hydroxymorphinan derivatives as neuroprotectants
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
WO2011107593A1 (en) 2010-03-05 2011-09-09 Dsm Ip Assets B.V. Process for the production of an uhmwpe article
WO2011153157A2 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
EP2598662A1 (en) 2010-07-02 2013-06-05 Aktiebolaget SKF Mechanical component and method for surface hardening
SG10201506761XA (en) 2010-09-03 2015-10-29 Teva Pharmaceuticals Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
CA2847736A1 (en) 2011-09-07 2013-03-14 IVAX International GmbH A new polymorphic form of pridopidine hydrochloride
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine

Also Published As

Publication number Publication date
BR112014024672A8 (pt) 2018-04-03
BR112014024672A2 (enExample) 2017-06-20
EA027748B1 (ru) 2017-08-31
KR20150013476A (ko) 2015-02-05
EA201491819A1 (ru) 2015-04-30
US20170266170A1 (en) 2017-09-21
CA2869145A1 (en) 2013-10-10
CN104470585A (zh) 2015-03-25
NZ630560A (en) 2016-11-25
ES2776678T3 (es) 2020-07-31
JP6177875B2 (ja) 2017-08-09
US20200000785A1 (en) 2020-01-02
AU2013243461A1 (en) 2014-11-06
MX2014011971A (es) 2015-01-16
JP2015515475A (ja) 2015-05-28
WO2013152105A1 (en) 2013-10-10
EP2844346A1 (en) 2015-03-11
EP2844346B1 (en) 2020-01-01
HK1206297A1 (en) 2016-01-08
IL234831A0 (en) 2014-12-31
US20130267552A1 (en) 2013-10-10
US11207308B2 (en) 2021-12-28
EP2844346A4 (en) 2015-11-18
ZA201407726B (en) 2016-05-25

Similar Documents

Publication Publication Date Title
ZA201407726B (en) Pharmaceutical compositions for combination therapy
ZA201703992B (en) Inhalable pharmaceutical compositions
ZA201503594B (en) Pharmaceutical compositions
ZA201501930B (en) Pharmaceutical composition
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
IL266415A (en) Innovative pharmaceutical composition
ZA201409020B (en) Pharmaceutical formulation
SI2814473T1 (sl) Farmacevtske sestave za kombinirano terapijo
GB201205164D0 (en) Pharmaceutical compounds
GB201420971D0 (en) Therapeutic composition
IL217807A0 (en) Therapeutic compositions
ZA201502987B (en) Pharmaceutical composition
GB201202027D0 (en) Pharmaceutical compounds
GB201211153D0 (en) Pharmaceutical compositions
PT2814473T (pt) Composições farmacêuticas para terapia de combinação
IL238075A0 (en) pharmaceutical preparations
GB201219234D0 (en) Pharmaceutical compositions
GB201213303D0 (en) Pharmaceutical compositions
ZA201400751B (en) Pharmaceutical composition
GB201204810D0 (en) Pharmaceutical compositions
GB201221130D0 (en) New pharmaceutical composition
GB201207628D0 (en) New pharmaceutical composition
GB201207701D0 (en) New pharmaceutical composition
GB201211406D0 (en) Pharmaceutical formulations
GB201211403D0 (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed